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Summary
It is well established that abnormally high levels of 
maternal serum alpha-foeto protein ( msAFP ) are associated, 
in the second trimester, with pregnancies affected by open 
neural tube defects ( NTDs ), More recently, low levels of 
msAFP, low levels of unconjugated oestriol ( UE3 ), and high 
levels of human chorionic gonadotrophin ( HCG ) have been 
associated with trisomy 21 pregnancies and this, in 
conjunction with the known correlation between trisomy 21 
and maternal age risk, has been used as the basis for 
population screening in the second trimester.
However, screening at this stage of pregnancy carries the 
inherent disadvantages of late diagnosis and thus late 
termination of affected pregnancies. This study set out to 
investigate the levels of the above three analytes ( AFP, 
HCG, UE3 ), in maternal serum sampled from pregnancies in 
the first trimester, to determine their potential as 
detectors of trisomy 21 and NTDs at this stage of foetal 
development.
Between January 1987 and April 1990 a series of 14,000 
serum samples were prospectively collected from women 
between 6 and 15 weeks pregnant who were routinely attending 
three local hospitals for ante-natal care. Upon receiving 
the samples, the clotted red blood cells were spun down and 
the serum separated into two aliquots, one for immediate use 
and one to be kept in frozen storage. Each sample was
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allocated a unique number and this was entered into a 
computer database system along with the patient’s details. 
The computer inputs these patient numbers into a daily 
worksheet and they were then assayed for AFP along with the 
routine second trimester samples. The HCG and UE3 assays 
were carried out separately and at a later date on the 
stored frozen samples. Within this series 16 trisomy 21, 5
trisomy 18, 1 trisomy 13 and 14 open NTD pregnancies were
identified and the serum samples isolated for later use. In 
addition to these there was a twin pregnancy, in which one 
foetus was affected with spina bifida and one unaffected, 
and another pregnancy in which the foetus was affected by 
both spina bifida and gastroschisis. From the total series 
of samples a set of 632 controls was selected in order to 
determine median values for each gestational age. The sample 
size for each gestation was as follows: 14 at 6 weeks, 45 at 
7 weeks, 69 at 8 weeks, 71 at 9 weeks, 68 at 10 weeks, 69 at 
11 weeks, 69 at 12 weeks, 68 at 13 weeks, 68 at 14 weeks, 
and 69 at 15 weeks.
The respective levels of the three analytes studied were 
determined by Immuno-Radiometric assays ( IRMA ) , in the 
cases of AFP and HCG, and by Radio-Immuno assay ( RIA ) for 
UE3. AFP levels were assayed using an in-house method which 
employs a two-site IRMA with Iodine-125 labelled monoclonal 
anti-AFP and polyclonal anti-AFP Sepharose solid phase. 
Separation is achieved by bead settlement in a sucrose 
density gradient.
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The HCG levels were assayed by use of a commercial kit, 
supplied by Serono. This uses three monoclonal antibodies to 
HCG, two of which are labelled with Iodine-125. The third 
antibody is labelled with fluoroscein and binds to the 
B-subunit. Separation is achieved by use of a sheep 
antiserum to fluoroscein coupled to a magnetic solid phase 
which binds to the HCG-monoclonal antibody complex. Due to 
the sensitivity of this assay it was necessary to dilute the 
sera 1:500 with horse serum.
The UE3 RIA was also a commercial kit, supplied by 
Amersham. Because this kit was designed for the second 
trimester it was necessary to adapt this assay to increase 
its sensitivity and thus render it useful as a first 
trimester test. After several trials optimum results were 
obtained by using the supplied standards at 20% with the 
sample sera and all other reagents at 100% volume. The RIA 
depends on competition between oestriol in the serum and 
Iodine-125 labelled oestriol for a limited number of binding 
sites on oestriol specific rabbit antibody. Separation is 
again by magnetic polymer particles.
For each of the three analytes, the concentration varies 
with gestation. As the gestational age increases the AFP 
level rises steadily from about 1.4 KU/L at 6 weeks to 5.84 
KU/L at 10 weeks and to 23.67 KU/L at 15 weeks. HCG levels 
rise rapidly to a peak of 98 IU/ml at 8 weeks and fall 
again, levelling off to around 20 IU/ml at about 20 weeks. 
UE3 levels increase slowly at first to about 0.46 nmol/L
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then, at around 11 weeks, rise more steeply as gestation 
progresses.
The sera from the 36 abnormal, pregnancies were then 
assayed and the results converted into multiples of the 
median (MoM) for each analyte at the stated gestation for 
that pregnancy. In the group of 16 trisomy 21 pregnancies 
the median MoM values for each analyte were as follows: 
AFP 0.65 (p< 0.02), HCG 0.97 (p<0.52), UE3 0.67 (p<0.01)
In the group of 5 trisomy 18 pregnancies median MoMs for 
each analyte were: AFP 0.71, HCG 0.27, UE3 0.34 
The median maternal age for these autosomal trisomies was 29 
years, ranging from 21 to 43 years of age.
None of the 14 pregnancies with open NTDs had msAFP levels
which were considered to be elevated in the first trimester 
sampling, that is > 2.0 MoMs for the stated gestation.
However when compared to their matched samples all 14 cases 
had significantly raised msAFP levels in the second
trimester. From these results it is clear that biochemical 
screening for NTDs in the first trimester is not reliable 
using these analytes and a separate program to screen for 
NTDs in the second trimester will continue to be necessary.
With regard to Down’s syndrome pregnancies, in this study, 
intact HCG varied little from the median value in trisomy 21 
pregnancies in the first trimester suggesting that it may
not be useful in a screening program. It can also be seen 
that the median MoMs for AFP and UE3 in this group are 
virtually identical and significantly reduced. However,
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there is some correlation between these markers (Correlation 
Coefficient r=0.22) indicating that they cannot be used as 
independent measures of risk in the first trimester. 
However, more recent studies indicate that the use of a free 
^?-HCG assay, rather than intact HCG, greatly improves first 
trimester screening efficiency having a median MoM of 1.96 
in trisomy 21 pregnancies. Thus, using a combination of AFP, 
or UE3, free ^?-HCG and maternal age, screening for 
chromosomal abnormalities at any gestation from 7 to 20 
weeks may be possible.
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1. Introduction
1.1
Since modern medical and nursing care have greatly reduced 
perinatal mortality and morbidity, genetically determined 
diseases and congenital malformations have become 
increasingly important factors of ill health in the 
community. It is therefore natural that those diseases with 
the highest birth incidences and severest pathologies have 
been the ones studied with the greatest interest. Amongst 
these, and of specific interest here, are the neural tube 
defects ( NTDs ) and chromosome abnormalities, particularly 
trisomy 21 ( Down’s syndrome ).
1.2 Neural Tube Defects
Neural tube defects have a relatively high birth incidence 
albeit with wide geographical variations. Typically quoted 
as 1-3/1000 ( Connor and Ferguson-Smith, 1992a ), NTDs
principally comprise anencephaly ( failure of the anterior 
neuropore to close ) and spina bifida ( failure of neural 
tube closure further down ). The two conditions are equally 
frequent and coexist in approximately 20% of cases. Other 
malformations, especially exomphalos, may also coexist. 
Several sub-divisions of spina bifida are made but of 
particular interest here is the distinction between "open"
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and "closed" lesions. In 15-20% of cases an intact layer of 
opaque tissue covers the lesion and are thus termed closed 
lesions. These tend to cause less neurological disability 
than open lesions where there is little or no covering 
tissue. The majority of cases, however, are open NTDs where 
the lesion is exposed and foetal metabolites can pass 
directly into the amniotic fluid from exposed capillaries 
and may even enter the maternal circulation. Thus only the 
open lesions are detectable biochemically.
Work done in the early 1970s ( Brock & Sutcliffe, 1972; 
Leek et al, 1973; Brock et al, 1973; Seller et a l , 1974;
Harris et al, 1974; Wald et al, 1974; Brock et al, 1974 )
indicated an association between, initially, high levels of 
amniotic fluid alphaf etoprotein ( AFP ) and NTDs and, 
subsequently, high levels of maternal serum AFP ( msAFP ) 
and NTDs. However, the relatively small sample sizes of 
these studies led to the setting up of the first UK 
Collaborative Study in January 1975, reporting in 1977 
(Report of UK Collaborative Study on Alphafetoprotein in 
Relation to Neural Tube Defects, 1977). This large study, of 
some 18,684 unaffected pregnancies and 301 NTD pregnancies, 
confirmed the association between high msAFP and NTD 
pregnancies, further concluding that the optimum serum 
sampling time was between 16-18 weeks gestation. The study 
also recommended the use of multiples of the normal median 
(MoMs ), as opposed to percentiles, and suggested a cut-off 
level of > 2.5 MoM.
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It had already been clear by the early 1970s that, due to 
the overlapping distributions of msAFP from affected and 
unaffected pregnancies ( Fig. 1 ), msAFP measurement would
not be a useful diagnostic test but that it could form the 
basis of an effective screening program. This has proved to 
be the case, the first ante-natal serum screening programs 
run for NTDs were established in the mid-1970s and such 
screening is now widely available throughout the UK. A blood 
sample is taken from the pregnant woman, usually at 16 or 17 
weeks gestation, and assayed for AFP. Should the AFP be 
above a certain cut-off level ( greater than 2.0 MoM in the 
west of Scotland ) a second sample is requested and if this, 
also, indicates a high risk of an NTD then a detailed 
ultrasound scan and amniocentesis may be recommended. The 
amniotic fluid sample is assayed for AFP by 
immunoelectrophoresis ( Brock & Sutcliffe, 1972 ) and,
following other findings in relation to NTDs, also assayed 
for acetylcholinesterase to obtain a diagnostic result 
(Smith et al, 1979 ). These screening programs typically
identify 100% of cases of anencephaly and 88% of open spina 
bifida. (cf. amniocentesis which identifies 100% of
anencephal ics and more than 98% of open spina bifidas, 
Ferg’uson-Smi th, 1983 ). In the west of Scotland, screening
75-80% of the pregnant population, this program has resulted 
in a 74% reduction of NTD births in the region 
(Ferguson-Smith, 1983).
Further studies of analytes other than AFP, such as human
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Figure 1. Overlap in the Distributions of AFP in Normal 
Pregnancies and those affected by NTDs.
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chorionic gonadotrophin ( HCG ) and unconjugated oestriol 
(UE3), have been carried out in an attempt to improve 
screening efficiency ( Canick et al, 1990 ). These indicated 
no significant changes in spina bifida pregnancies for 
either HCG or UE3 though both analytes were below the median 
level in anencephalic pregnancies, this being especially 
low for UE3 with a median MoM of 0.17.
1.3 Down’s Syndrome
Trisomy 21, or Down’s syndrome, was the first chromosome 
abnormality identified in humans ( Lejeune et al, 1959 ) and 
was also the first to be prenatally diagnosed, by
amniocentesis, in 1969 ( Connor and Ferguson-Smith, 1992b ). 
Although over 600 chromosomal diseases are now known, 
trisomy 21 is still the most common with a birth incidence 
of 1.3/1000 ( Valenti et a l , 1968 ). It is the
single commonest cause of mental retardation in newborns and 
is responsible for about 25% of all moderate to severe
mental handicap in children of school age. The IQ is usually
less than 50 and other complications may include congenital 
heart malformations, epilepsy, hypothyroidism, cataracts and 
leukaemia. Puberty is often delayed and incomplete and
presenile dementia common after 40 years of age.
An association between an increased risk of a Down’s
syndrome pregnancy and increasing maternal age has been 
known since the early 1930’s ( Penrose, 1933; Jenkins,
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1933). This increases from a birth risk of 1:1500 at 20 
years of age to 1:1000 at 29, 1:380 at 35, 1:112 at 40 and
about 1:30 at 45. However, although women 35 years and over 
have a significantly greater risk they only account for 
about 30% of Down’s births because of the vast bulk of the 
pregnant population ( over 90% ) are under this age.
Therefore offering amniocentesis to all women over 35 years 
of age could detect a maximum of 30% of Down’s pregnancies. 
Clearly, due to the slight risk of foetal mortality 
associated with amniocentesis, (0.5-1.0%), this could not be 
routinely offered to all women under 35. Thus some method of 
screening the pregnant population to identify women at an 
increased risk of a Down’s pregnancy was desirable.
Due to the serendipitous persistence of a woman pregnant 
with what turned out to be a trisomy 18 (Edward’s syndrome ) 
infant, Merkatz and his colleagues ( in 1984 ) conducted a
retrospective study of amniotic fluid and msAFP levels in 
pregnancies associated with prenatally diagnosed chromosome 
abnormalities. This data was first presented in 1983 and 
published in 1984 ( Merkatz et al, 1984 ) concluding that,
while no special pattern emerged for trisomic pregnancies 
when looking at amniotic fluid, there was a significant 
association between such pregnancies and low msAFP. Many 
subsequent studies ( Cuckle and Wald, 1984; Fuhrmann et a l , 
1984; Tabor et a l , 1984; Cowchock and Ruch, 1984; Seller,
1984; Spencer and Carpenter, 1985; Murday and Slack, 1985; 
Hershey et al, 1985; Doran et al, 1986; Brambati et al ,
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1986; Bogart et al, 1987; Canick et al, 1988 ) confirmed
this association indicating a typical value of 0.72 
multiples of the normal median ( MoM ) for Down’s syndrome 
pregnancies. This and other work ( esp. Cuckle et al, 1987 ) 
suggested that the current AFP screening programs for NTDs 
could, in conjunction with known maternal age specific risk 
data ( Ferguson-Smith & Yates, 1984 ), be adapted to screen
for aneuploidies. This was first done in the UK in the 1980s 
and was introduced in the West of Scotland in 1987. These 
screening programs typically identify up to 40% of Down’s 
syndrome pregnancies, with a 6-7% false positive rate, 
compared with up to 30% detection and a 6.7% false positive 
rate by maternal age alone.
With a view to increasing both sensitivity and specificity 
a whole range of other maternal serum pregnancy protein 
markers have been studied in recent years. Chief amongst 
these analytes have been HCG, ( Bogart et al, 1987), and
UE3, ( Canick et al, 1988 ).
It has been known since the mid-1960’s that low levels of
HCG in early pregnancies is predictive of an abnormal 
outcome, commonly a spontaneous abortion ( Brody and 
Carlstrom, 1965 ). It was thus a prime candidate for
investigation and indeed the value of HCG in improving 
prenatal screening has been confirmed by several studies 
(Wald et al,1988a; Bogart et al,1989; Crossley et al, 1991Q,'). 
Wald et al (1988a) in a study of serum samples from 77 
Down’s syndrome pregnancies with 385 normal controls,
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indicated that high levels of maternal serum HCG ( msHCG ) 
were associated with trisomy 21 pregnancies. The level for 
the median HCG concentration in such pregnancies was 2.04 
MoM. This and another large study, of 7815 unaffected 
pregnancies and 15 Down’s syndrome pregnancies ( Crossley et 
al, 1991 ), indicated that the integration of HCG into a
screening program using AFP and maternal age risk could 
provide a detection rate of over 60% with a false positive 
rate of 5.6%.
UE3 has also been shown to be useful ( Canick et al, 1988; 
Wald et al, 1988b ) having a median value of 0.73 MoM in
Down’s syndrome pregnancies and in combination with maternal 
age data and AFP yields a detection rate of 45% with a false 
positive rate of 5.2%. These analytes have now been 
integrated into many screening programs, either HCG singly 
or HCG and UE3 together, and in conjunction with AFP and 
maternal age data can provide a Down’s detection rate of 
upwards of 60% with a 5% false positive rate, though the 
value of including UE3 in such programs has been questioned 
( Macri et al, 1990a ).
As stated above, several other analytes have been examined 
such as pregnancy-specific B1 glycoprotein (SP-1) ( Bogart,
1987,1989; Bartles and Lindemann, 1988; Knight et al, 1989; 
Graham et al, 1992), pregnancy associated plasma protein-A
(Stabile et al, 1988), human placental lactogen (hPL) and
progesterone ( Knight et al, 1989 ), and free-p-HCG (FBHCG)
( Macri et al, 1990b ). These have met with varying degrees
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of success and work is ongoing. It remains the case, 
however, that AFP, HCG and UE3 are the main focus of 
interest and as they are the three analytes which were 
examined in this present study they will be considered in 
more detail.
1.4 Alphafetoprotein
First identified by Bergstrand and Czar in 1956, human 
AFP is a glycoprotein with a molecular weight of about 
65,000 and a single polypeptide chain of 590 amino acids. 
Though no conclusive evidence has yet been produced, since 
it is closely linked to albumen, it has been speculated that 
it functions as a transport protein ( Ruoslahti and Hirai, 
1978 ) . While the early source of AFP is almost certainly in 
the yolk sac, production later shifts to the foetal liver 
though some evidence exists of synthesis in the 
gastro-intestinal tract ( Gitlin, 1975 ) . Production of AFP 
in the foetus begins with the development of the yolk sac at 
around 4-6 weeks and the foetal serum concentration peaks at 
about 13 weeks gestation ( Gitlin, 1975 ). In normal,
non-pregnant adults the serum concentration is between 2-20 
ng/ml, corresponding to about 1.6-16 KU/L ( Gitlin and 
Boesmann, 1966; Talermann et al, 1978 ). Maternal serum AFP 
rises from normal adult levels at about 4-6 weeks gestation, 
peaking at between 200-400 KU/L around 25 weeks ( Gitlin, 
1975 ).
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1.5 Human Chorionic Gonadotrophin
HCG is a sialoglycoprotein with a molecular weight of 
about 40,000. It is composed of two sub-units, termed and 
p, the larger sub-unit being virtually identical to that 
of the pituitary hormones human luteinising hormone ( hLH ), 
human follicle stimulating hormone ( hFSH ), and human 
thyroid stimulating hormone (hTSH ). Variation in
biological activity is determined by differences in the 
p sub-unit and it is these which allow the molecules to be 
immunologically distinguished ( Rothfield et al , 1974 ). The 
site of HCG production is the placental syncytio-trophoblast 
where it is produced in large quantities and functions in 
early pregnancy to sustain the corpus luteum beyond its 
normal lifetime, ensuring as a result the continued 
production of oestrogen and progesterone which help to 
maintain the endometrium, thus allowing pregnancy to proceed 
( Lunenfeld and Insber, 1978). In later pregnancy the 
placenta can produce adequate amounts of the steroid 
hormones itself and HCG production is reduced. HCG also 
serves to stimulate the production of testosterone by the 
testes of the foetal male necessary for normal 
masculinisation. It has further been proposed that placental 
secretion of HCG helps to protect the foetus from the 
maternal immune system ( Adock et al, 1973 ).
Detectable amounts of HCG may be found in the maternal 
serum and urine very soon after conception with levels
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rising to a peak during the third month of gestation. Levels
then fall steadily until about 20 weeks and then remain
fairly constant until term.
The actual values range from about 50 mlU/ml after the
first week’s gestation to a peak of between 30 and 200 IU/ml 
at 12 weeks. This falls to around 15 IU/ml at 20 weeks and 
persists at this value for the duration of pregnancy 
(Vaitukaitus et al, 1977).
1.6 Unconjugated Oestriol
Oestriol belongs to the oestrogens, which are one of the 
five major classes of steroid hormones derived from 
cholesterol, and is produced predominantly in the 
foeto-placental unit (Diczfalusy and Mancuso, 1969 ).
Hydroxylated steroid intermediates, formed mainly by the 
foetal adrenals (Frandsen and Stakemann, 1964; Siiteri and 
MacDonald, 1966; Adlercreutz and Luukkainen, 1970 ), are
metabolised to oestriol by the syncytio-trophoblast cells of 
the placenta and are conjugated in the maternal liver to
form glucuronides and sulphates ( Lauritzen, 1971 ). Thus
oestriol exists in the blood as a mixture of the
unconjugated form and several conjugates. The level of UE3 
in the maternal serum increases slowly through the first
trimester, then rapidly after that. Oestriol in the maternal 
blood has a half-life of only 20-30 minutes, thus variations 
in foetal-placental production should be rapidly reflected
-16-
by changes in maternal serum levels.
1.7 First Trimester Screening
All the above work on screening for foetal neural tube 
defects and chromosome abnormalities has focussed on 
analytes in the second trimester, especially from 16-20 
weeks gestation following the recommendation of 16-18 weeks 
as optimum for NTD detection in the 1977 UK Collaborative 
Study. However, any screening at this stage of pregnancy 
carries the intrinsic disadvantages of late diagnosis and 
consequent late termination of affected pregnancies . This 
has led to considerable interest in the levels of marker 
analytes in the first trimester. Several studies as early as 
the mid-1980's (Brambati et al , 1986; Barkai et al, 1987 ) 
reported low msAFP in first trimester Down’s pregnancies. 
These had a low sample size, however, and a larger study, 
looking at AFP, HCG and UE3^was carried out by Cuckle et a l , 
1988. This took samples from 22 affected Down’s pregnancies, 
at gestations from 7-12 weeks, each being matched with 5 
samples from unaffected pregnancies at the same gestation. 
The study showed lowered median values of 0.35 MoM for UE3 
and 0.72 MoM for AFP. No significant change in HCG levels 
was reported. This study also recommended that further 
investigations on a larger scale be undertaken.
A significant problem with much of the above work, 
valuable though it was, is, as was suggested by Cuckle et al
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in their 1988 study, the relatively small sample sizes. In 
addition, the majority of the samples had been obtained from 
patients prior to first trimester chorionic villus sampling 
procedures where the indication for this sampling was 
advanced maternal age and they are thus not truly 
representative of the screened population. Further, all 
looked at Down’s syndrome exclusively, none including any 
NTDs. It was with a view to contributing to the data 
available that this study was undertaken.
1.8 Aims
Four principle objectives were identified:
(i) To optimise the available AFP, HCG and UE3 assays for
first trimester maternal serum samples.
(ii) To establish normal ranges for AFP, HCG and UE3 at 
each week of gestation to be studied.
(iii) To investigate the levels of AFP, HCG and UE3 in 
maternal serum from known trisomy 21 pregnancies 
from an unselected pregnant population for the 
detection of Down’s syndrome in the first trimester.
(iv) To investigate the levels of maternal serum AFP,
HCG and UE3 in pregnancies affected by neural tube 
defects from an unselected pregnant population
in the first trimester.
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2. Materials and Methods.
2.1 Maternal Serum Samples
Between January 1987 and April 1990 maternal serum samples
were prospectively collected from 14,000 pregnant women at
between 6-15 weeks gestation who were routinely attending
ante-natal clinics in the West of Scotland, From each sample
an aliquot was used for routine maternal serum
alphafoetoprotein ( msAFP ) screening, the remainder being 
o
stored at -20 C for later use. Between July 1989 and April 
1990 first trimester serum samples from three of these local 
clinics were also routinely assayed for human chorionic 
gonadotrophin ( HCG ).
Three methods of assessing gestational age are routinely 
used:
1. From the date of last menstrual period ( LMP ).
2. Estimation by clinical examination.
3. From the bi-parietal diameter assessed by 
ultrasonic scan.
Where estimates of gestation by the different methods 
varied, the following hierarchy was used: if the date of the
last menstrual period was certain then gestation was 
calculated on that basis; if uncertain, or unknown, then 
estimation by ultrascan was used; if an ultrascan had not 
been carried out then gestation estimation by uncertain 
dates was used and failing that, by clinical examination.
-19-
Where assessment by ultrascan differed by two or more weeks 
from estimation by dates, even if certain, then the 
ultrascan estimate was used. For the majority of patient 
samples used as controls,the different methods of measuring 
gestational age concurred. Within this series of 14,000 
samples, 16 trisomy 21, 5 trisomy 18, 1 trisomy 13 and 14
open NTD pregnancies were identified and the sera isolated 
and frozen at -20 C for later use. From the total series a 
set of 632 controls were selected in order to determine 
median values for each gestational age. The sample size for 
each gestation was as follows:
14 at 6 weeks, 45 at 7 weeks, 69 at 8 weeks, 71 at 9 weeks, 
68 at 10 weeks, 69 at 11 weeks, 69 at 12 weeks, 68 at 13 
weeks, 68 at 14 weeks, 69 at 15 weeks.
Patient details and assay results were stored in a 
computer database though no data analysis was undertaken at 
this stage. Most patients with continuing, viable 
pregnancies returned for routine serum screening in their 
second trimester and this further data was entered into the 
database. The outcomes of the above pregnancies were then 
awaited and the clinical results of any abnormal births 
recorded, these again being entered into the database.
2.2 Immunoassay Methodology
Two assay types were used in the determination of the
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levels of the three analytes that were studied: a
Radio-Immuno assay ( RIA ) in the case of Unconjugated 
Oestriol ( UE3 ), and Immuno-Radiometric assays ( IRMA ) in 
the cases of AFP and HCG.
RIAs have rapidly proliferated in range and type since the 
first publication by Yalow and Berson in 1960, offering as 
they do the advantages of sensitivity, specificity and 
simplicity. RIAs and IRMAs utilise antibody adsorbed onto a 
solid-phase. However, the ways in which this reagent is used 
is quite different for the two assay types.
In RIAs a limited and constant concentration of antibody 
is reacted with a much larger, varying amount of antigen in 
the presence of a fixed and constant amount of
radio-labelled antigen which competes with the native
antigen for binding sites on the antibody. Thus the amount 
of radio-labelled antigen which is bound to the antibody / 
solid-phase complex varies inversely to the original total 
concentration of antigen. That is, the more radioactivity 
measured at the end-point, the less antigen there was 
present in the original sample.
With IRMAs, however, the varying concentrations of antigen 
are reacted with a constant but, this time, ’excess’ amount 
of radio-labelled antibody. Therefore, after equilibrium is 
reached, the amount of bound antigen is directly
proportional to the original concentration of the antigen. 
That is, the more radioactivity measured at the end-point, 
the more antigen there was present initially.
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Both RIAs and IRMAs discriminate between the bound and 
unbound fractions by use of an appropriate antibody which is 
adsorbed onto a solid-phase. This is used to produce a 
precipitate, containing the bound fraction, and a 
supernatant containing the unbound fraction which is 
discarded.
2.3.1 Alphafetoprotein Assay
The assay used for both this first trimester study and the 
routine second trimester samples was an in-house IRMA method 
( Stevenson et al, 1987 ). This assay has been in constant
use for routine ante-natal screening in the west of Scotland 
area since 1985 and the laboratory participates in the UK 
External Quality Assurance Scheme ( EQAS ).
Two antibodies to AFP are employed in this assay, one 
monoclonal and one polyclonal. The monoclonal anti-AFP is 
radio-labelled with Iodine-125 while the polyclonal antibody 
is attached to a Sepharose solid-phase. Separation of the 
bound fraction is achieved by bead settlement, under 
gravity, in a sucrose density gradient.
2.3.2 Alphafoetoprotein Assay Methodology
25 ul aliquots of serum are diluted with 200 ul of assay 
buffer ( EPPS, Tween 20, Na ). This is carried out in
duplicate for each sample, standard and quality control. In
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each assay there are 10 standards, 0-9, 5 quality controls
at the begining and end of the assay, and a drift control 
every 15 samples ( see Table 1 for values and assay layout). 
To this is added 200 ul of tracer mix, (270ul radio-labelled 
anti-AFP, 14 ml anti-AFP solid-phase, 40ml assay buffer, and
1.2 ml sheep serum per 240 tube assay). The assay tubes are 
incubated at room temperature for 2 hours on an orbital 
shaker at about 300rpm. 1 ml of isotonic saline wash, ( 0.9% 
NaCl, Tween 20 ), is then added to each tube. A peristaltic
pump and inspiration manifold are then used to add 3 ml of 
concentrated sucrose solution ( lOOg/L, Tween 20 ) to each
tube FROM THE BOTTOM UP. In this way the bound fraction is 
floated to the top of the tube whence the Sepharose beads 
are left to settle for one hour.
At the end of this time an aspiration manifold, attached 
to an electric vacuum pump, is used to suck off the upper 
layers containing the unbound fraction. ( Both the 
inspiration and aspiration manifolds deal with 40 tubes at a 
time ).The bound fraction is then resuspended with another 
lml of saline wash, to reduce non-specific binding, and 
again floated on 3 ml of the sucrose solution. After a 
further one hour settlement any remaining unbound fraction 
is removed as before.
Having been previously mounted in the appropriate racks, 
the assay tubes are transferred to a Packard Cobra gamma 
multi-counter which counts 10 tubes simultaneously. The raw 
counts ( 1 min./tube ) are stored to floppy-disk and the
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Assay Tube Nos. Tube Contents Values ( KU/L )
1-2 Standard 0 0.00
3-4 " 1 0.94
5-6 " 2 1.76
7-8 " 3 5.29
9-10 " 4 10.50
11-12 " 5 29.70
13-14 " 6 61.60
15-16 " 7 126.00
17-18 " 8 245.00
19-20 " 9 511.00
21-22 Qual. Cont. 1 5.30
23-24 " M 2 16.80
25-26 " " 3 79.40
27-28 " " 4 275.00
29-30 " ” 5 BLANK
31-32 Drift control 115.00
33-34 Sample
II If
tl II
61-62 Drift Control
( And again after every 14 samples )
I
231-232 Qual. Cont. 1
233-234 " " 2
235-236 " " 3
237-238 " " 4
239-240 " " 5
Table 1: AFP Assay Layout and Standard Values.
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data then processed with the SASPRO calculation package 
which uses the 4-parameter mass action model ( Edwards and 
Ekins, 1983 ). These results are then transmitted downline
to a DEC PDP 11/84 mainframe computer and entered into the 
database.
2.4.1 Human Chorionic Gonadotrophin Assay
The assay type used, as for AFP, was an IRMA. A 
proprietary kit was used, that being the HCG MAIA Clone kit, 
supplied by SERONO Diagnostics. This measures intact HCG, 
not the dissociated subunits. It employs THREE high affinity 
monoclonal antibodies, two of which are radio-labelled with 
Iodine-125 and the third labelled with fluoroscein. These 
bind to unique sites on both subunits of the intact 
molecule. After a short incubation, separation is achieved 
by addition of a sheep antisera to fluoroscein which is 
coupled to a magnetic solid-phase thus enabling a rapid and 
consistant sedimentation of the bound fraction.
2.4.2 Human Chorionic Gonadotrophin Assay Methodology
Using solely the reagents supplied with this kit the 
highest concentration of HCG measurable without dilution is 
500 mlU/ml. Thus, after preliminary investigation, a 1:500 
dilution was carried out on all patient samples and internal 
quality controls. This was done using horse serum with 0,2%
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Sodium Azide as an antibacterial agent. The dilutions were
carried out in two steps: 10 ul of sample is added to 190 ul
of horse serum ( 1:20 ); after vortex mixing, 10 ul of this
dilution is added to 240 ul of horse serum ( 1:25 ) and
again vortex mixed, giving a total dilution of 1:500. The
kit standards, were used at the concentrations supplied and
the sample results derived were scaled up accordingly.
Quality controls, in addition to the basic positive and
negative controls supplied with the kit, were made up using
pooled maternal sera of known gestation which were then
o
aliquoted and frozen for storage at -20 C, ( see Table 2 for
assay values and layout )
Next, 25 ul of diluted samples, controls and standards are
dispensed, in duplicate, into reaction tubes. To all of
these is added 500 ul of the radio-labelled anti-HCG. The
tubes are vortex mixed then incubated in a water bath at 
o
37 C for 15 min. After this time 200 ul of magnetic anti- 
-fluoroscein solid-phase is added, the tubes vortexed and 
incubated at room temperature for a further 5 min. They are 
then transferred to magnetised racks whence the solid-phase/ 
HCG/ antibody complex precipitates out after a minute or so. 
To reduce non-specific binding the supernatant is drained 
off and 500 ul of wash buffer ( TRIS ) is added, the tubes 
again vortexed and the separation step repeated. After again 
discarding the supernatant the tubes are left to drain for 
about 10 mins.
The tubes are then removed to a gamma multi-
Assay Tube Nos. Tube Contents Values ( IU/ml )
1-2
3-4
5-6
7-8
9-10
11-12
13-14
15-16
17-18
19-20
21-22
23-24
53-54
85-86
117-118
119-120
* Qual. Cont.
Table 2:
Standard 0 0
1 5
2 10
3 25
4 100
5 250
6 500
Serono +ve. 26
Qual. Cont. 1 75*
" ” 2 12*
Drift Control 295
Sample
ft
ft
Drift Control 295
Sample
ft
Drift Control 295
Sample
ft
Qual. Cont. 1  7 5
2 12
+ 2: These two quality controls were made up 
from pooled 9 week and 17 week maternal 
serum respectively. The serum was first 
pooled, then aliquoted and frozen. The 
values given are thus mean values.
HCG Assay Layout with Standard Values.
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-counter which counts 10 tubes simultaneously, each one for 
two mins. The raw counts, standard curve and results were 
recorded onto the computer print-out and later typed into a 
database/ statistics package ( SPSS/PC+ ) for subsequent 
analysis.
2.5.1 Unconjugated Oestriol Assay
Unlike the AFP and HCG IRMAs, an RIA method was employed 
here. Again this was a commercial kit, the "Amerlex-M 2nd. 
Trimester Unconjugated Estriol RIA Kit*’ manufactured by 
Amerlite Diagnotics Ltd. Being specifically a second 
trimester kit it was necessary to carry out an extensive 
preliminary investigation into increasing the sensitivity of 
the kit to suit first trimester levels.
This RIA method depends on competition between UE3 in the 
serum and Iodine-125 labelled oestriol for a limited number 
of binding sites on a rabbit anti-oestriol. The proportion 
of the radio-labelled bound fraction is inversely related to 
the concentration of oestriol in the serum sample. 
Separation of this bound fraction is achieved by use of a 
magnetic solid-phase to which a further antibody is 
attached.
2.5.2 Adaptation of the Unconjugated Oestriol Assay Kit
Several experiments were carried out to try and improve
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the assay sensitivity. These trials were all done using the 
same set of early gestation samples, randomly selected from 
the pool and covered most of the range of gestations studied 
( Samples at 6 and 7 weeks gestation could not be used due 
to shortage of numbers ).
2.5.3
The first assay variation was simply to use the standards 
and reagents at 1/2 normal volumes while retaining full 
volumes for the sample sera. This proved very 
unsatisfactory, however, due to the volume specific reaction 
dynamics of RIAs.
2.5.4
The next trial used the assay standards at 20% volume with 
all assay reagents at full volume. Sample sera were used at 
both 20% and 50% of normal in an attempt to conserve the 
limited supplies of sera. This again gave inconsistant 
results.
2.5.5
The third trial again used standards at 20% but made up to 
50% of normal volume with pooled male human serum. Again, 
sample sera were tried at 20% and 50% of normal. This method 
yielded improved results though again with insufficient 
consistancy.
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2.5.6
The next trial again ran standards 20% but this time made 
up to 100% volume with pooled male human serum. All reagents 
and sample sera were used at full volumes. This proved the 
most satisfactory and consistant variant. Final sample 
values were obtained by using this method and multiplying 
all results by 0.2. Unfortunately, having to use full volume 
aliquots ( lOOul ) of sera resulted in being unable to 
obtain results for some of the abnormal samples due to there 
being insufficient sera available.
2.5.7 Unconjugated Oestriol Assay Methodology
20ul aliquots of the standards and 100 ul aliquots of the
sera, both in duplicate, were dispensed into the reaction
tubes ( Table 3 ). Then, lOOul aliquots of Iodine-125
labelled oestriol were added to each tube. A further 1.0 ml
of anti-oestriol solid-phase was added to all the tubes and
these were then vortex mixed and incubated in a water bath 
o
at 37 C. for 1 hour. Upon removal the reaction tubes are 
transferred to magnetised racks and left for 15 mins. for 
the bound fraction to precipitate. The supernatant is then 
discarded and the tubes allowed to drain on blotting paper 
for 20 mins. Following this the tubes are transferred to a 
gamma multi-counter, each one for 2 mins., the raw counts 
printed out and these were later entered into a database / 
statistical package ( SPSS/PS+ ).
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Assay Tube Nos. Tube Contents Values ( nmol/L )
1-2 Standard 0 0.00
3-4 " 1 1.10
5-6 M 2 2.20
7-8 " 3 4.90
9-10 " 4 9.20
11-12 " 5 19.50
13-14 " 6 48.00
15-16 Qual. Cont. 1 27.00*
17-18 " " 2 1.50*
19-20 Drift Control 30.00**
21-22 Sample
If II
Vt M
51-52 Drift Control
M Sample
11 11
83-84 Drift Control
1 Sample
Tf 11
117-118 Qual. Cont. 1
119-120 " " 2
* Qual. Cont. 1 + 2 :  These quality controls were made up
from pooled maternal serum from 16 
weeks and 8 weeks respectively. The 
serum was first pooled, aliquoted 
and then frozen. The values given 
are mean values.
** Drift Controls: These too were made up from pooled
maternal serum, again at 16 weeks 
though in this case from a different 
batch to that of Quality Control 1. 
The values given are mean values.
Table 3: UE3 Assay Layout with Standard Values.
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2.6 Statistical Methods Employed in Data Analysis
Having obtained the normal control values for all three 
analytes, a median value for each analyte at each week of 
gestation was derived by weighted linear regression. This 
was done using the statistics software package SPSS/PC+ 
which also served as the database to which all the analyte 
assay data was stored.
Upon obtaining these normal medians the results from the 
abnormal pregnancies were converted to multiples of these 
medians ( MoMs ) by simply dividing the value for the 
abnormal sample at a given gestation by the normal median 
value at that gestation.
Any deviations from normal values in the abnormal 
populations were tested for significance using the 
Mann-Whitney test. This test, also known as the Wilcoxon 
test, does not require any assumptions about the shape of 
the underlying distributions. It tests the hypothesis that 
two independent samples come from populations having the 
same distribution. The form of the distribution need not be 
specified. The test does not require that the variable be 
measured on an interval scale; an ordinal scale is 
suf f icient.
The p-values derived using this test were again obtained 
using SPSS/PC+.
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3. Results Section
(■
3.1.1 Assay Optimisation
The in-house AFP assay employed was of sufficient 
sensitivity ( 0.6 KU/L ) and precision (! 10 .8% at 6.3KU/L ) 
as to require no modification for first trimester samples. 
(Sensitivity being defined as the mean of the zero standard 
plus two standard deviations ) .
The HCG assay, as with sample sera from second trimester 
pregnancies, was modified by a 1:500 dilution of maternal 
sera using horse serum. With this modification the assay 
sensitivity was 0.8 IU/ml and the assay precision was 5.7% 
at 10 IU/ml.
The UE3 assay required several modifications for first 
trimester work before a satisfactory method was found, the 
original modification described by Canick et al ( 1988 ) and 
Wald et al ( 1988b ) being inappropriate due to differences
in the Amersham UE3 assay kits used ( the assay used here 
was the Amersham Amerlex 2nd. Trimester kit ). Two criteria 
were considered in modifiying this kit: the desirability of
conserving sera from abnormal pregnancies and the need to 
increase the assay sensitivity to deal with first trimester 
sera.
3.1.2 Unconjugated Oestriol Assay Optimisation
The first variation, using the standards and reagents at
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1/2 volumes with the sample sera at full volume, proved very 
unsatisfactory resulting in a poor curve fit and an 
inability to fit some results to the curve.
3.1.3
The next trial used the assay standards at 20% volume with
all other reagents at full volume. Sample sera were used at 
both 20% and 50% of normal volume in attempt to conserve 
sera. This gave poor sensitivity ( 0.22 nmol/L ) and many
sample results were too high to fit onto the the standard 
curve.
3.1.4
The third trial again used the standards at 20% but made 
up to 50% of normal volume using pooled male human sera. 
Again sample sera were tried at both 20% and 50% of normal 
volumes. This gave poorer sensitivity ( 0.28 nmol/L ) though
the sample sera results did map better to the curve at 20% 
of normal volume.
3.1.5
The next trial again ran the standards at 20% of normal 
volume but made up to 100% using pooled male human serum. 
All reagents and sample sera were used at full volumes. This 
proved the most satisfactory and consistant variant and 
yielded a sensitivity of 0.12 nmol/L with a precision of 
21.3% at 0.3 nmol/L.
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Final sample values were obtained using this 
method and multiplying all results by a factor of 0.2. 
Unfortunately, having to use full volume aliquots ( lOOul ) 
of sera resulted in being unable to obtain results for some 
of the abnormal samples due to a shortage of available sera.
3.2 Normal Controls
Having established the criteria for assessing gestation, a 
total pool of 632 samples with a range of gestations from 6 
to 15 weeks were selected and assayed for each of the three 
analytes. Stable median values were obtained at, typically, 
around 50 samples. This sample size was not possible, 
however, for the gestational periods of 6 and 7 weeks due to 
a combination of insufficient sample numbers in the total 
series at these gestations or samples failing to meet the 
gestation assessment criteria ( Table 4 ) . In addition, the
full set of matched controls were not available for each 
analyte, again due to a shortfall in sera volume. The 
results from these assays are summarised as median values in 
Table 5 and are presented in full in Appendix I. They are 
also presented as graphs of concentration against gestation 
in Figures 2, 3 and 4 showing the spread of the data around 
the medians.
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Number of Samples per Analyte
Sample Gestation AFP HCG UE3
List No. ( Weeks ) = = = = = = = = =
1-69 15 69 63 66
70-140 14 68 67 63
141-208 13 68 65 61
209-278 12 69 61 57
279-347 11 69 62 62
348-421 10 64 68 66
422-492 9 71 66 66
493-561 8 69 66 66
562-618 7 37 45 45
619-632 6 13 12 14
Total No . Samples Assayed 597 575 566
Missing Cases (*) 35 57 66
Total Sample Number 632 632 632
(*) = Due to insufficient volumes of sera
Table 4. Breakdown of Sample Numbers Assayed to Establish 
Median Values for Normal Controls.
Analytes
;tation AFP HCG UE
i Weeks) (KU/L) (IU/ml) (nmol/L)
6 1 .41 71.0 0.32
7 3.21 81.0 0.34
8 3.99 98.0 0.37
9 4.49 84.0 0.40
10 5.84 75.0 0.46
11 10.12 72.0 0. 70
12 13.51 64.0 0.82
13 17.08 49.0 1 .45
14 22.08 39.5 2.02
15 23.69 34.0 2.67
Table 5: Median Analyte values in Normal Pregnancies.
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Figure 2. AFP versus Gestation. 
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Figure 3. HCG versus Gestation.
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Figure 4. UE3 versus Gestation.
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3.3 Abnormal Samples
Using the above normal control median data the results 
from pregnancies with known abnormal outcomes were studied. 
The serum samples from these pregnancies had been randomly 
inserted into the assays used to determine normal controls 
at which times nothing was known about them other than their 
laboratory identification numbers. Multiples of the median 
(MoMs) were then calculated for each abnormal sample by the 
simple formula:
Sample analyte value at gestation X
---------------------------------------  = MoM for Sample
Median analyte value at gestation X
From the prospective series of 14,000 pregnancies a total 
of 16 trisomy 21 and 14 open NTDS were identified. In 
addition, 5 trisomy 18, 1 trisomy 13, 1 exomphalos, 1
anencephaly with spina bifida and gastroschisis and a twin 
pregnancy, where one foetus had spina bifida and one was 
unaffected, were also identified. However, given the small 
numbers of these latter cases, discussion will be largely 
confined to the trisomy 21 and NTD cases.
Having been converted to MoMs, the results from these 
abnormal pregnancies are presented in Tables 6, 7 and 8.
These results are also presented as scatter plots ( Figs. 5 
and 6 ) and the raw data is presented in full in
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Appendix-II. Significance of any deviations from the normal 
median values was assessed by the Mann-Whitney test, the 
results of which are presented in Table 9.
3.3.1 Alphafetoprotein
As may be seen from Fig. 5, AFP levels are significantly 
lower ( p = 0.02 ) than the median normal in Down’s
pregnancies, having a median MoM of 0.65. With regard to 
open NTDs, no significant difference from normal values was 
detected ( p = 0.75 ), as may be seen from Fig. 6.
3.3.2 Human Chorionic Gonadotrophin
Intact HCG levels in first trimester Down’s pregnancies 
show no significant deviation from normal median values, 
having a median MoM of 0.97 ( p = 0.52 ). However, HCG
levels show some reduction in trisomy 18 pregnancies, having 
a median MoM of 0.27 ( Fig. 5).
Again, no significant differences were observed in open 
spina bifida ( p = 0.61 ), though all three anencephalics
had values > 2.0 MoM ( Fig. 6 ).
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Analytes
Trisomy 21 Gestn. AFP HCG UE3
Cases (Weeks) (MoM) (MoM) (MoM)
1 13 0.88 2.88 0.90
2 8 0.53 0.87 0
3 9 0.87 1.45 0.50
4 13 0.47 1.96 1.09
5 13 0.99 1.41 0.84
6 9 0.22 1.62 1.25
7 9 0.89 1.10 0
8 7 0.31 0.96 0.82
9 14 0.50 6.08 0.68
10 11 0.10 0.63 0.26
11 13 0. 70 0.98 NA
12 10 2.05 0.93 0.65
13 14 0.60 0.96 0.37
14 10 1.20 0.77 0.46
15 13 0.59 0.96 0.89
16 10 1.13 0.43 0
* NA = Not Available
Table 6: Analyte Results as Multiples of the normal Median 
( MoM ) in Trisomy 21 pregnancies.
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Analytes
Gestn. 
(Weeks)
AFP 
MoM )
HCG 
( MoM )
UE3 
( MoM )
Trisomy 18 13 0. 70 0.27 0.41
11 0.59 0.58 NA *
11 0.59 0.14 0.34
8 1.00 0.13 0.62
12 0.79 0.48 0.28
Trisomy 13 15 0.35 1.03 1.90
* NA = Not Available
Table 7: Analyte Results in Trisomy 18 Pregnancies as
Multiples of the normal Median ( MoM ) plus values 
for the Trisomy 13 Pregnancy.
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ABNORMALITY Gestn. AFP HCG UE3
==_======== (weeks) (MoM) (MoM) (MoM)
Spina bifida 9 0.67 0.69 1.38
10 0.86 1.80 1.39
10 0.69 0.83 1.61
11 0.59 0.56 0.77
11 1.09 0.88 0.96
12 1.41 1.20 1.60
12 1.04 0.25 1.30
12 1.41 1.28 0.85
12 1.18 0.61 NA*
13 1.05 0.80 0.63
14 2.90 1.11 1.01
Anencephaly 8 0.75 2.32 2.54
8 0.50 2.09 2.00
10 0.86 2.20 0.74
Exomphalos 12 2.15 3.61 1.27
Anencephaly with
spina bifida and
gastroschisis 12 1 . 78 1.47 0. 98
Twin pregnancy:
1 spina bifida,
1 unaffected 11 2.96 0.68 1.00
*NA = Not Available
Table 8: Analyte Results from Pregnancies with Non-
-Chromosomal Defects Expressed as Multiples 
of the Normal Median ( MoMs ).
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Mann-Whitney Tests
Analyte p-value
Trisomy 21 AFP 0.02
HCG 0.52
UE3 0.0005
Open NTDs AFP 0.75
HCG 0.61
UE3 0.18
Table 9: Outcome of Mann-Whitney tests on the Results
from the Abnormal Pregnancies.
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3.3.3 Unconjugated Oestriol
UE3 levels in trisomy 21 affected pregnancies show a 
highly significant ( p = 0.0005 ) drop below normal values, 
with a median MoM of 0.67. Levels in trisomy 18 pregnancies 
are even more depressed with a median MoM of 0.34 ( Fig.5).
Open spina bifida again shows no significantly abnormal 
pattern ( p = 0.18 ), though anencephaly levels do appear
elevated with two of the three having values > 2.0 MoM
(Fig. 6).
3.3.4 Other Abnormalities
The results from these pregnancies are also presented in 
Tables 7 and 8. The values for AFP, especially, in 
pregnancies with non-chromosomal defects does appear 
elevated from the normal, but no reliable conclusions may be 
drawn given the sample sizes.
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4. Discussion
4.1 Chromosome Abnormalities
The results presented here for Down’s syndrome pregnancies, 
identified from a true screening population, show that AFP 
and UE3 levels are significantly reduced in affected 
pregnancies but that intact HCG, the most powerful marker in 
the second trimester, is virtually unaltered. These results 
are again presented, in Table 10, along with the data from 
previous significant studies for purposes of comparison. As 
may be seen from this table, the data from this study 
accords well with the findings of many other studies
(Brambati et al, 1986; Barkai et a l , 1987; Cuckle et al,
1988; Milunsky et al, 1988; Mantigh et al , 1988; Bogart et
al, 1989; Brock et al , 1990; Nebiolo et al,1990; Kratzer et
al, 1991; Crandall et al, 1991; Johnson et al, 1991; Check
et al, 1990; van Lith et al, 1991; Shalev et al , 1992; van
Lith reporting, 1992; Wald et a l , 1992 ),
The data presented for trisomy 18 pregnancies in the first 
trimester is, at the time of writing, unique in both case
numbers and in the range of analytes examined. While AFP
levels show some decrease, both UE3 and HCG levels are
considerably depressed which mirrors the pattern in the
second trimester.
With regard to intact HCG, although no significant 
deviation from normal median values has been demonstrated in
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Trisomy 21 Trisomy 18
Normal Case AFP HCG UE3 Case AFP HCG UE3
Reference Controls Numbers MoM MoM MoM Numbers MoM MoM MoM
Brambati 446 8 0.75 NA NA 2 0.50 NA NA
et al.
( 1986 )
Barkai 99 2 0.65 NA NA NA NA NA NA
et al.
( 1987 )
Cuckle 110 22 0.72 NQ 0.35 NA NA NA NA
et al .
( 1988 )
Brock 63 21 0.71 1.43 0.67 NA NA NA NA
et al.
( 1990 )
This 632 16 0.65 0.97 0.67 5 0.71 0.27 0.34
Study.
( 1993 )
N A : Data Not Available 
N Q : Data Not Quoted
Table 10: Comparison of median MoMs from the current study with 
those from previous studies of trisomy 21 and 18 in 
the first trimester.
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the present study, a modest increase ( 1.43 MoM ) was noted
by Brock et al ( 1990 ) in a series of 21 Down’s syndrome
pregnancies. More recent studies which looked at free-B HCG 
( FBHCG ) have found the pattern of high maternal serum 
levels associated with second trimester Down’s pregnancies 
reflected in the first trimester also. (Macri et al , 1990b;
Spencer et al, 1992 )
The similarity of the above relationships, that is, low 
AFP and UE3 and high FBHCG, might lead one to hope that the 
detection rates for Down’s syndrome achieved in the second 
trimester may also be attainable in the first trimester. 
Clearly, though, further prospective studies will be 
necessary to determine whether this is indeed viable.
As for the one case of trisomy 13 found in the series, 
while there is a marked drop in the AFP level ( see Table 7) 
the most striking feature is the very high HCG level ( 3.61
MoM ). However, this is only one case and further data are 
required before any conclusions can be drawn.
4.2 Neural Tube Defects
The inclusion of msAFP estimation in routine second 
trimester prenatal screening programs not only contributes 
to the detection of Down’s syndrome pregnancies but has a 
key role in the detection of open neural tube defects at 
this stage of pregnancy, to which end it was originally 
introduced. However, this study, in common with previous 
ones ( UK Collaborative study, 1977; Shalev et al , 1992 ),
has been unable to demonstrate any significant deviation
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from normal median values for the analytes AFP, intact HCG 
and UE3 in first trimester pregnancies with open spina 
bifida.
HCG and UE3 levels in the few cases of anencephaly do show 
a marked increase and this is of some interest as it is 
exactly the opposite of the trends identified by Canick et 
al in 1990. Their study gave a median MoM of 0.75 for HCG 
compared with >2.0 MoM here and, perhaps more strikingly, a 
very low median MoM of 0.17 for UE3 compared with a marked 
increase to over 2.0 MoMs in two out of the three in this 
study. The Canick study, though, was much larger with some 
19 anencephalics and further data are required before 
concluding that the current results are of significance.
Overall, however, there is no significant pattern thus 
moving screening for chromosome abnormalities to the first 
trimester would have the disadvantage of loss of detection 
of NTDs. Although ultrasound scanning is an effective 
diagnostic measure for NTDs in the second trimester in a 
high risk group defined by maternal serum screening, its 
sensitivity as a primary screening measure is open to 
question ( Whittle, 1992 ). This is illustrated by the 14
cases of open NTDs reported in this study where all except 
one case was not diagnosed until after investigation of a 
routine second trimester elevated msAFP result. It is 
therefore concluded that, for the near future, first 
trimester biochemical screening for NTDs will continue to be 
impracticable and that second trimester screening will
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retain its central role in such ante-natal programs.
4.3 Estimating Gestation
Another factor of central importance in all areas of 
ante-natal screening is the accurate estimation of 
gestational age. It is well recognised that accurate 
ascertainment of this is critical in the calculation of MoMs 
and hence the derivation of any maternal risk. The current 
method usually employed is to round gestation down to the 
nearest whole week. That is, if accurate dates for the last 
menstrual period indicate a gestation of 13 weeks and 5 days 
then gestation is taken as 13 weeks. Clearly, there is some 
significant margin for error here and there may be a case 
for examining the possibility of reckoning gestation in days 
and therefore determining maternal risk values in a more 
continuous manner. This may be of even greater value given 
that the rate of change of maternal serum levels of some 
analytes varies at different ranges of gestational age. For 
example, from 6 to 12 weeks UE3 levels increase only 
moderately and thus an ’error’ of a few days in estimating 
gestation would have little effect. However, from 12 weeks 
onwards the rise in levels increases substantially and those 
same few days ’error’ may effect a significant alteration of 
maternal risk ( see Fig. 4 ). From 6 to 12 weeks there is a
mean rise of 0.08 nmol/L/week in the median value of UE3, 
while from 12 weeks to 15 weeks there is a mean rise in UE3
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levels of 0.61 nmol/L/week: almost an eight-fold rate
increase. However, refining the use of gestation to single 
days will require the estimation of median values in the 
control population for each individual day of gestation to 
allow accurate conversion of analyte values to MoMs.
4.4 Alternative Analytes
With regard to both Down’s syndrome and NTDs, continued 
examination of maternal serum pregnancy markers, other than 
those discussed above, will certainly be an area of intense 
activity. Already many of the alternative analytes which 
have been investigated in the second trimester have also 
been investigated in the first trimester. Mentioned 
previously, free-p HCG ( FBHCG ), ( Macri et a l , 1990b;
Spencer, 1991 ), is of considerable interest showing a
marked elevation in both the second and first trimesters 
unlike intact HCG which, as stated, shows no significant 
deviation from normal levels in the first trimester. Others 
include pregnancy-specific Bl-glycoprotein ( SP-1 ) and 
placental alkaline phosphatase ( PALP ), (Brock et a l , 
1990); progesterone ( Kratzer et al, 1991 ); cancer antigen
125 (CA125 ), ( Check et al, 1990; van Lith et al, 1991 );
placental protein 14 ( PP-14 ), ( Wald et a l , 1992 ).
Apart from FBHCG, few of these studies, all of which 
looked only at Down’s pregnancies, indicated that any of the 
analytes mentioned would be particularly useful. At the time
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of writing only the work on pregnancy associated plasma 
protein-A, ( PAPP-A ), ( Wald et al, 1992; Brambati et al,
1993 ) appears to offer a significantly large deviation from 
normal median values ( 0.27 MoM in Down’s pregnancies ) to
warrant consideration for inclusion in first trimester 
screening. However, PAPP-A shows significant correlation 
with FBHCG in the first trimester ( Aitken et a l , 1993) and
the values are unaltered in Down’s syndrome pregnancies in
the second trimester ( Knight et al, 1993 ). More data are
required to assess the rate of change in PAPP-A MoMs across 
gestation. This whole area is still evolving and no doubt 
will be aided by an understanding of the basic 
patho-physiology.
4.5 Conclusions
From the results of the present study, and others 
previously mentioned, several analytes in maternal serum 
such as AFP, UE3, FBHCG and PAPP-A can be identified as 
possible candidates for a first trimester screening program 
for foetal chromosome abnormalities. However, in the first
trimester AFP is no longer the first choice marker, as it is 
in the second trimester screening programs, as it does not 
predict NTDs at this stage although it still a useful 
predictor of Down’s syndrome. The most powerful marker in 
the first trimester is free-jB HCG ( FBHCG ) which, in
combination with AFP is predicted to give a 54% detection
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rate at a 5% false positive rate ( Aitken et a l , 1993 ). UE3 
and PAPP-A each show significant median shifts in Down’s 
syndrome pregnancies in the first trimester, but are 
technically difficult to measure at the low concentrations 
prevalent in very early pregnancy. The advantage of using 
AFP/FBHCG in combination with maternal age would be 
consistency with current second trimester screening 
programs, as this marker combination could be used at any 
gestation from 7-20 weeks.
If pre-natal screening for chromosome abnormalities became 
routine before 15 weeks gestation, detection of NTDs would 
have to rely on the use of detailed ultrasonography. While 
anencephaly is readily detected by ultrasound in the first 
trimester, spina bifida is difficult to detect before the 
second trimester, and there may be a case for continuing to 
offer AFP screening at 16-18 weeks gestation as a primary 
screening test for NTDs in combination with ultrasound.
Little is understood about the mechanisms which cause 
variations in the levels of certain maternal serum markers 
in chromosomally abnormal pregnancies. The different 
patterns of variations seen between markers and between 
first and second trimesters ( Table 11 ) is difficult to
rationalise with simple explanations of foetal/placental 
immaturity as originally proposed by Wald et al ( 1988a ).
Further studies on the control of production and excretion 
of these markers in appropriate foetal and placental tissues 
are necessary to elicit these mechanisms in order to refine
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the selection of the optimal markers for the various stages 
of the screening process.
However, given the public debate engendered by the anxiety 
created in expectant mothers by current second trimester 
screening, any future multi-stage schemes would be heavily 
dependent on the careful provision of trained, skilled 
counselling to ensure that pregnant women fully understand 
the complexities of the screening process and are thus not 
rendered unduly anxious.
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Analyte First Trimester Second Trimester
AFP
UE3
HCG (intact) 
FBHCG (free-p) 
PAPP-A 
SP-1
Low
Low
Normal
High
Low
Low
Low
Low
High
High
Normal
High
Low - Below Normal Median Values. 
Normal - At the Normal Median Value. 
High - Above the Normal Median Value.
Table 11: Comparison of Marker Analyte Levels in First and 
Second Trimester Down’s Syndrome Pregnancies.
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Appendix I : Normal Control Raw Data
Sort
Lab No Code Gestn
150003 1 15
150615 1 15
150117 1 15
150640 1 15
150287 1 15
150106 1 15
150378 1 15
150008 1 15
150543 1 15
150306 1 15
150574 1 15
150582 1 15
150531 1 15
150585 1 15
150533 1 15
150607 1 15
150456 1 15
150282 1 15
150223 1 15
150222 1 15
150313 1 15
150220 1 15
150229 1 15
151847 1 15
151965 1 15
151090 1 15
151344 1 15
151803 1 15
151352 1 15
151959 1 15
151823 1 15
151676 1 15
151134 1 15
151071 1 15
151176 1 15
150891 1 15
150647 1 15
150814 1 15
150866 1 15
150649 1 15
152043 1 15
151207 1 15
150644 1 15
151741 1 15
151672 1 15
150711 1 15
150868 1 15
810127 1 15
Maternal AFP
Age (KU/L)
25 24.79
28 23.04
26 11.84
24 24.24
27 34.03
41 47.35
35 16.26
23 25.94
25 30.43
28 33.62
31 19.25
31 59.95
29 30. 76
28 17.17
30 16.31
22 26.44
22 12.38
29 21.67
25 20. 72
21 27.18
20 35.04
29 23.75
22 26. 78
23 29.68
31 12.01
19 16.55
16 34.85
26 25.58
17 20.87
21 10.63
32 49.98
28 28.73
31 22.22
21 45.47
26 17.38
25 23.28
26 23.62
23 34.98
27 63.19
30 25.88
19 25.10
27 8.00
21 15.48
30 4.70
17 22.60
22 22.80
29 27.55
30 26.00
HCG UE3
(IU/ml) (nmol/L)
68 1.94
49 3.08
84 2.18
32 3.27
34 3.44
19 3.64
38 2.48
26 2.64
N/A 3. 70
20 6.26
37 2.72
23 3.52
87 3.54
20 3.34
65 0.80
21 5.96
23 1. 70
23 1.99
20 1.46
19 1.82
20 3.98
33 2.42
37 2.46
40 1.88
70 1.81
20 2.52
26 5.57
25 3.32
50 2.76
99 0.40
43 3.57
35 3.64
N/A N/A
50 4.58
N/A 0.70
30 1. 77
19 4.24
23 4.08
51 3.04
37 2.46
33 0.95
N/A 0.73
49 1.98
36 0.70
35 3.77
20 2 .06
33 3.24
N/A N/A
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Sort Maternal AFP
Lab No Code Gestn Age (KU/L)
HCG UE3
(IU/ml) (nmol/L)
150706 15 26 46.00 35 5.56
151590 15 31 15.00 18 2.98
150709 15 22 21.80 37 2.44
150690 15 25 4.87 91 0.52
150655 15 29 15.85 16 2.30
151294 15 26 33.17 63 2.74
150897 15 28 16.05 47 2.66
150892 15 24 21.39 34 3.96
151667 15 30 22.24 19 2.67
150707 15 25 23.80 55 2.20
151434 15 31 24.69 20 4.34
151936 15 24 8.67 87 0.82
151937 15 32 36.69 19 2.82
151557 15 34 24.00 22 3.10
151929 15 24 33.44 N/A N/A
151911 15 22 2.31 20 0.14
151595 15 29 10.00 95 0.38
151181 15 24 23.24 37 3.86
152017 15 18 39.38 19 2.56
151400 15 28 19.01 13 2.26
151045 15 22 12.00 54 1.44
150215 14 26 20.44 44 2.98
150213 14 20 10.98 55 0.84
150628 14 22 21.83 25 3.82
150166 14 26 16.92 52 1.92
150244 14 28 27.45 44 1 .46
150137 14 34 16.10 30 1.04
150291 14 31 14.64 40 2.22
150195 14 35 30.95 35 N/A
150498 14 29 38.82 86 2.40
150377 14 37 15.92 12 N/A
150167 14 38 23.77 30 N/A
150492 14 32 24.83 15 3.40
150511 14 31 17.59 21 2.00
150259 14 21 18.33 0 5.28
150047 14 24 20.85 32 1 .84
150147 14 27 20.86 41 2.52
150234 14 27 36.55 25 4.82
150273 14 26 13.13 28 3.30
150013 14 27 26.17 23 2.02
150077 14 36 20.73 85 1.78
150062 14 24 25.89 18 0.20
150061 14 33 38. 71 24 1.84
150494 14 22 22.87 65 2.14
150466 14 27 6.92 67 0.48
150243 14 24 35.08 33 1.60
150240 14 27 24.70 54 1.36
150451 14 29 17.43 35 1.98
150349 14 24 20.15 23 2.28
150103 14 27 15.88 72 1.06
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L
150221 1 14 36 35.39 46 15.60
150563 1 14 14 12.58 69 2.34
150407 1 14 26 12.12 55 1.30
150430 1 14 33 23.44 17 2.70
150100 1 14 22 10.87 47 1.52
150802 1 14 30 4.58 125 2.40
151907 1 14 22 27.18 32 1.94
152007 1 14 31 27.26 51 1.34
151986 1 14 22 44.73 58 2.22
151685 1 14 27 36.09 67 3.17
151347 1 14 22 25.25 29 1.21
150793 1 14 27 22.94 45 2.80
151221 1 14 24 17.21 46 1.50
150876 1 14 25 26.14 39 2.00
150834 1 14 17 33.61 52 3.80
151880 1 14 29 11. 71 58 2.50
150862 1 14 26 51.50 28 2.94
151327 1 14 27 23.76 31 3.12
150779 1 14 27 19.23 30 1.82
150943 1 14 28 20.40 49 N/A
151925 1 14 38 23.24 48 1.76
151292 1 14 24 25.78 32 2.40
151868 1 14 23 21.16 20 1.65
150683 1 14 27 26.40 43 2.40
151380 1 14 28 22.07 37 1.46
151160 1 14 28 14.31 N/A N/A
150745 1 14 25 22.33 17 0.86
151705 1 14 29 30.58 71 2.66
151566 1 14 16 44.00 27 2.85
151227 1 14 28 26.42 55 0.78
151317 1 14 23 30.40 45 1.57
150656 1 14 34 19.94 20 2.32
150700 1 14 31 19.90 51 3.34
151508 1 14 20 19.10 86 1.14
151397 1 14 20 14.42 58 2.75
151040 1 14 26 11.00 N/A N/A
151950 1 14 29 19.86 N/A 2.24
153329 1 14 28 21.43 N/A N/A
152708 1 14 25 12.00 N/A N/A
152342 1 14 22 N/A 20 4.77
153288 1 14 30 N/A 13 2.25
153226 1 14 27 N/A 18 2.16
150082 1 13 33 45.56 29 1.92
150331 1 13 27 25.56 27 1.68
150334 1 13 24 7.31 56 0. 78
150613 1 13 36 17.58 274 1.80
150145 1 13 23 13.22 115 2.18
150288 1 13 27 18.66 49 2.22
150444 1 13 31 14.08 23 1.30
150411 1 13 34 19. 72 25 1.78
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Sort Maternal AFP
Lab No Code Gestn Age (KU/L)
HCG UE3
(IU/ml) (nmol/L)
150261 13 23 11.69 21 1.62
150488 13 22 30.82 31 1.14
150113 13 29 37.45 N/A 1.78
150022 13 25 9.96 50 N/A
150366 13 24 8.07 43 1.30
150012 13 30 15.76 75 N/A
150108 13 34 26.61 48 1.44
150257 13 26 19.13 52 1.50
150151 13 32 18.84 59 1.54
150048 13 25 24.27 31 1.14
150408 13 28 14.20 35 0.90
150263 13 30 14.91 58 1.66
150540 13 29 10.19 57 2.10
150004 13 29 21.59 27 1.50
150448 13 35 14.75 55 1.16
150118 13 29 33.29 67 2.42
150389 13 20 12.87 71 1.86
150547 13 23 24.00 62 2.06
150445 13 25 20.77 62 0.82
150038 13 22 13.31 18 0.52
150401 13 27 21.28 29 1.26
150075 13 29 7.39 120 1.10
150612 13 32 18.54 55 0.88
150414 13 29 25.57 31 2.36
150115 13 30 15.95 36 1.58
150410 13 27 11.64 31 1 .08
150399 13 28 12.28 37 0.76
150162 13 22 9.23 38 1.02
150016 13 35 15.34 47 1.88
150242 13 27 25.88 30 1. 18
150454 13 28 16.98 43 1 . 74
150609 13 25 15.67 55 1 .32
150386 13 27 19.12 91 1.54
150230 13 33 16.63 82 1 .34
150552 13 27 21.55 32 0.90
150560 13 25 11.08 67 1 .80
150632 13 17 17.51 115 0.82
150203 13 25 31.33 54 N/A
151063 13 20 5.96 103 N/A
151649 13 19 17.21 55 0.92
151120 13 24 6.88 N/A N/A
150998 13 20 11.55 24 N/A
151303 13 23 19.56 36 1 .06
151173 13 29 13.48 33 1 .24
151682 13 21 16.83 17 1.55
151093 13 26 25.62 N/A N/A
151799 13 23 23.19 42 2.58
151838 13 36 18.67 75 1.18
151260 13 19 20.00 64 1.18
150757 13 32 37.57 147 1 .45
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
151118 1 13 29 9.12 34 1.56
151898 1 13 25 13.83 58 1.64
151430 1 13 42 28.04 35 1.34
151533 1 13 30 20.16 30 0.98
151910 1 13 27 19.53 78 1.04
150922 1 13 30 22.17 75 2.01
151798 1 13 40 14.05 15 1.20
151127 1 13 24 20.88 54 1.31
151555 1 13 21 12.00 49 0.99
150665 1 13 35 9.01 73 1.28
150000 1 12 29 11.00 N/A N/A
150001 1 12 40 9.00 N/A N/A
150480 1 12 27 9.51 70 0.56
150056 1 12 31 27.04 54 1.28
150092 1 12 25 23.49 39 0.74
150098 1 12 27 19.37 N/A 0.80
150095 1 12 36 23.80 72 1.66
150091 1 12 30 10. 78 47 N/A
150508 1 12 30 17.58 55 0.94
150590 1 12 22 12.08 55 0.96
150141 1 12 32 10.52 45 0.84
150007 1 12 32 7.39 N/A N/A
150021 1 12 37 19.59 65 N/A
150315 1 12 26 11.40 62 0.66
150372 1 12 32 12.85 20 N/A
150032 1 12 31 32.09 71 1.12
150193 1 12 33 14.46 55 0. 70
150390 1 12 36 N/A N/A N/A
150119 1 12 24 5.03 69 1 .66
150256 1 12 27 10.49 67 1.96
150442 1 12 30 12.46 67 N/A
150130 1 12 22 10.33 36 0.80
150398 1 12 35 10.32 57 1.18
150002 1 12 34 24.56 49 0.82
150114 1 12 30 13.88 57 0.42
150184 1 12 24 10.17 80 N/A
150583 1 12 30 5.82 26 1.20
150473 1 12 28 16.71 48 0.64
150606 1 12 29 19.60 50 0.50
150159 1 12 22 6.20 52 0.48
150403 1 12 29 1.13 98 0.22
150409 1 12 38 5.00 40 0.72
150253 1 12 18 6.93 107 0.62
150153 1 12 29 15.70 79 1.30
150633 1 12 18 5.21 135 0.82
151339 1 12 30 8.13 83 0.98
150737 1 12 20 12.60 75 0.57
151966 1 12 37 12.34 64 0.36
151442 1 12 20 3.36 75 N/A
151964 1 12 17 15.24 79 0.50
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
151386 1 12 25 30.78 N/A 1.42
151859 1 12 26 25.71 71 0.88
150754 1 12 16 17.16 62 1.16
151707 1 12 27 9.18 72 0.56
151805 1 12 37 25.21 39 0.54
151300 1 12 23 5.06 45 0.42
150750 1 12 24 7.88 N/A 0.48
151515 1 12 21 8.17 44 0.92
151113 1 12 20 17.47 109 N/A
151021 1 12 21 15.82 N/A N/A
150838 1 12 27 12.62 56 0.62
151254 1 12 26 6.00 N/A N/A
150835 1 12 23 13.63 56 1.08
151980 1 12 18 9.63 29 1.26
152010 1 12 32 16.47 69 0.88
150971 1 12 27 11.90 107 0.85
150920 1 12 31 8. 74 95 0.76
151095 1 12 26 10.33 63 0.86
150953 1 12 27 27.10 186 1.50
152061 1 12 28 8.86 150 0.46
151425 1 12 19 3.05 49 0.24
150923 1 12 29 13.49 109 0.90
150968 1 12 22 7.28 92 0.32
150914 1 12 28 15.29 79 0.68
151546 1 12 21 13.70 55 0.90
151329 1 12 17 13.20 68 0.63
150935 1 12 21 4.21 52 0.34
151131 1 12 30 7.84 39 0.66
151147 1 12 30 17.51 74 1.12
151137 1 12 28 21.12 76 0.44
150040 1 11 24 22.81 78 0.62
150096 1 11 29 4.32 117 0.50
150078 1 11 32 8.75 71 0.44
150019 1 11 28 10.53 228 1.28
150622 1 11 25 9.26 165 0.48
150139 1 11 21 21.95 61 N/A
151161 1 11 26 29.01 N/A 0.84
150489 1 11 35 11.90 109 0.66
150014 1 11 29 9.38 137 0.34
150393 1 11 33 17.25 98 0.58
150510 1 11 29 9.83 62 N/A
150034 1 11 28 11.02 44 0. 72
150392 1 11 25 20.02 N/A 0.84
150049 1 11 32 14.72 103 0.98
150144 1 11 19 9.89 83 0.88
150639 1 11 33 15.14 78 1.18
150146 1 11 29 22.90 86 0.56
150026 1 11 25 16.08 44 0.76
150491 1 11 28 15.11 151 0.70
150148 1 11 35 13.66 51 0.62
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
150194 1 11 29 15.41 92 0.62
150371 1 11 25 22.52 47 N/A
150504 1 11 26 14.34 33 0.42
150635 1 11 28 7.71 53 0.62
151232 1 11 30 17.57 79 0.70
150294 1 11 30 5.36 48 0.82
150541 1 11 26 17.04 N/A N/A
150235 1 11 31 6.65 62 0.72
150260 1 11 30 5.52 69 0.82
150524 1 11 26 22.77 84 0.80
150079 1 11 27 4.81 77 0.32
150415 1 11 33 17.17 74 0.66
151181 1 11 27 11.22 N/A 0.66
150530 1 11 35 10.46 63 0.88
150519 1 11 28 16.84 100 N/A
150065 1 11 39 15.69 82 0.78
150782 1 11 20 2.77 70 0.44
151648 1 11 24 2.39 121 0.76
151065 1 11 20 15.98 N/A N/A
150762 1 11 26 25.18 25 0.74
150718 1 11 26 8.00 71 0.46
150843 1 11 31 8.27 60 1 .16
151216 1 11 20 4.56 48 0.88
151722 1 11 28 5.10 37 0.80
151717 1 11 23 6.51 59 0.53
150955 1 11 18 31.30 93 0.72
151461 1 11 22 6.80 70 0.52
151725 1 11 22 11.49 112 0.81
150719 1 11 28 9.17 99 0.52
150764 1 11 22 11.66 N/A 0.52
151445 1 11 30 7.53 46 0.35
151019 1 11 22 5.27 N/A N/A
150908 1 11 27 9.51 52 0.64
150860 1 11 31 10.40 45 0.46
150751 1 11 23 7.23 68 0.84
152060 1 11 26 6.68 73 0.44
151423 1 11 29 16.56 74 0. 70
151307 1 11 34 10.98 61 0.60
151258 1 11 28 4.00 59 0.66
151257 1 11 20 17.00 141 0. 72
151797 1 11 20 5.76 68 0.68
151518 1 11 25 8.17 134 0.98
152006 1 11 32 13.28 57 0.78
151067 1 11 29 24.06 114 1 .00
151457 1 11 26 5.99 59 0.42
151677 1 11 33 5.66 365 0.34
150660 1 11 32 8.37 75 0.70
151233 1 11 28 12.35 95 0.72
151715 1 11 30 7.69 54 0.74
150094 1 10 27 6.34 224 0.32
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Sort Maternal AFP
Lab No Code Gestn Age (KU/L)
HCG UE3
(IU/ml) (nmol/L)
150341 10 23 5.41 232 1.16
150055 10 17 5.84 68 1.14
150168 10 29 14.51 171 1.08
150093 10 21 6.48 139 0.16
150172 10 31 11.73 N/A 0.78
150340 10 25 5.51 95 0.34
150475 10 22 2.77 63 0.36
150478 10 28 9.23 N/A N/A
150169 10 29 20.22 43 N/A
150088 10 21 4.23 119 0.26
150427 10 20 8.41 63 1.02
150631 10 23 4.28 65 0.26
150335 10 21 8.98 186 0.34
150514 10 23 6.07 74 0.08
150290 10 29 5.24 77 0.42
150611 10 30 10.91 60 0.56
150589 10 27 5.34 118 0.58
150150 10 24 7.16 39 0.54
150076 10 25 5.30 90 0.52
150602 10 20 2.67 67 0.48
150520 10 34 4.44 39 0.30
150156 10 24 4.07 181 0.68
150562 10 38 4.26 82 N/A
150071 10 26 6.06 30 N/A
150739 10 20 5.00 86 0.94
150675 10 28 3.87 118 N/A
151477 10 15 5.94 76 0.61
151479 10 38 8.92 36 0.49
152036 10 22 3.18 71 0.88
151478 10 27 11 .09 151 0.59
151656 10 35 6.84 58 0 .89
150734 10 23 3.02 54 0.46
150977 10 28 6.22 41 0.44
150678 10 17 3.85 79 0.36
151197 10 22 3.45 69 0.00
151522 10 25 24.24 107 0.79
151808 10 23 19.24 57 0.41
151716 10 28 7.77 153 0.38
150939 10 20 8.57 92 0.54
151018 10 27 8.61 61 0.36
150873 10 20 4.58 90 0.52
151835 10 29 4.54 N/A N/A
151581 10 27 6.00 112 0.50
151214 10 22 5.96 93 0.47
151804 10 28 3.16 80 0.20
151981 10 29 4.03 73 0.38
151899 10 29 2.82 44 0.26
151529 10 24 3.66 144 0.44
151310 10 31 8.48 57 0.22
150919 10 24 2.35 31 0.32
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Sort Maternal AFP
Lab No Code Gestn Age (KU/L)
HCG UE3
(IU/ml) (nmol/L)
150859 10 26 5.13 156 1.02
151215 10 24 3.97 77 0. 72
150773 10 36 9.41 87 0.73
151308 10 31 3.52 42 0.28
151459 10 25 4.61 63 0.58
150942 10 24 6. 74 126 0.46
150671 10 26 12.91 65 0.52
151145 10 27 16.27 35 0.40
150941 10 30 6.86 55 0.40
151146 10 26 5.40 57 0.50
151735 10 33 4.01 61 0.59
151733 10 21 16.90 25 0.54
151671 10 20 8.11 87 0.47
153568 10 36 N/A N/A N/A
152921 10 30 N/A 101 0.24
152275 10 26 N/A 70 0.34
153571 10 34 N/A N/A N/A
152424 10 23 N/A 54 0.90
152102 10 35 N/A 97 0.60
152927 10 28 N/A 115 0.36
153210 10 26 N/A N/A N/A
152506 10 26 N/A 134 0.46
152129 10 26 N/A 46 0.46
150218 9 29 9.33 56 0.32
150474 9 33 4.32 101 0.38
150479 9 34 5.33 112 0.40
150553 9 33 3.22 91 0.24
150337 9 28 1.68 36 0.50
150505 9 32 2.44 99 0.40
150446 9 30 4.22 168 0.46
150402 9 31 33.82 64 0.34
150165 9 35 6.41 64 0.44
150413 9 23 5.98 104 0.40
150507 9 30 4.83 71 0.32
150140 9 25 8.54 158 0.86
150465 9 22 3.20 N/A N/A
150603 9 26 2.85 113 0.50
150312 9 21 10.61 99 0.38
150623 9 27 4.47 126 0.38
150518 9 23 8.47 108 0.28
150187 9 17 1.56 20 0.32
150101 9 30 3.23 117 0.48
150228 9 27 3.47 107 0.18
150559 9 26 2.54 131 0.32
150068 9 23 9.24 178 0.88
150129 9 27 4.85 68 0.80
150252 9 31 4.49 71 0.32
150158 9 29 7.08 95 0.26
150102 9 34 4.51 57 0.30
150517 9 24 1.39 86 0.56
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Sort Maternal AFP
Lab No Code Gestn Age (KU/L)
HCG UE3
(IU/ml) (nmol/L)
150280 1 9 34 9.12 76 0.58
150154 1 9 20 1.64 31 0.38
150251 1 9 32 7.50 198 0.46
152052 1 9 19 4.65 201 0.34
151654 1 9 17 13.95 N/A N/A
150740 1 9 23 7.33 40 0.40
152035 1 9 36 3.18 111 0.42
151066 1 9 18 5.28 N/A 0.68
151288 1 9 28 1.94 209 0.50
151483 1 9 22 3.14 58 0.51
151967 1 9 24 3.14 76 0.54
151062 1 9 21 0.56 N/A N/A
152032 1 9 29 3.74 145 0.56
152031 1 9 31 0.99 31 1.10
151305 1 9 20 7.64 108 0.97
151084 1 9 26 5.07 N/A N/A
151800 1 9 27 4.10 75 0.65
151879 1 9 25 14.43 75 0.48
152064 1 9 25 4.04 N/A N/A
151903 1 9 26 2.55 106 0.00
150959 1 9 28 9.42 47 0.46
151218 1 9 27 3.57 101 0.76
152009 1 9 32 7.16 140 0.14
151130 1 9 22 9.80 24 0.22
151112 1 9 19 7.94 84 0.30
151869 1 9 26 2.46 55 0.26
150836 1 9 26 4 . 99 72 0.34
150858 1 9 26 15.76 80 0.52
151874 1 9 25 4.37 75 0.52
151727 1 9 24 4.12 69 0.28
151168 1 9 27 4.42 39 0.50
150954 1 9 26 11.40 29 0.58
150854 1 9 26 4.35 59 0.30
151140 1 9 27 2.97 27 0.04
150667 1 9 31 3.47 154 0.56
150863 1 9 32 8.21 174 0.34
150369 1 9 27 5.38 66 0.32
151792 1 9 37 7.21 118 0.42
151739 1 9 24 3.42 102 0.59
151436 1 9 35 3.99 63 0.58
151209 1 9 20 6.73 41 0.22
151796 1 9 20 4.78 56 0.46
151983 1 9 27 3.34 93 0.00
151972 1 9 28 2.16 311 N/A
150339 1 8 30 2.64 40 0.30
150301 1 8 30 4.12 126 0.32
150211 1 8 18 3.20 200 0.52
150214 1 8 24 5.07 157 0.50
150292 1 8 31 3.25 41 0.28
150116 1 8 27 7.27 113 0.80
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
150006 1 8 26 4.39 125 0.42
150024 1 8 28 6.67 110 0.42
150262 1 8 28 4.05 233 0.52
150616 1 8 21 4.15 228 0.24
150111 1 8 32 3.99 159 N/A
150059 1 8 30 5.28 86 0.24
150417 1 8 26 3.00 N/A N/A
150126 1 8 31 5.65 127 N/A
150310 1 8 22 3.03 59 0.52
150385 1 8 19 2.48 59 0.58
150278 1 8 36 3.52 38 0.22
150436 1 8 23 1.00 27 0.10
150805 1 8 27 4.37 123 0.42
150735 1 8 25 1 .71 69 0.42
151652 1 8 23 3.41 123 0.28
150980 1 8 29 3.28 16 0.32
152034 1 8 23 1.35 13 0.30
151979 1 8 26 1. 72 147 0.56
150855 1 8 30 9.63 64 0.36
151577 1 8 26 3.00 83 0.51
151523 1 8 29 1.89 93 0.49
150915 1 8 23 4.33 125 0.42
151349 1 8 21 5.48 41 0.73
151897 1 8 30 4.51 71 0.54
151345 1 8 37 0.89 95 1.21
151877 1 8 32 1.83 161 0.44
151578 1 8 34 5.00 112 0.25
151960 1 8 22 2.78 109 0.46
151616 1 8 31 3.00 186 0.53
151217 1 8 27 0.49 43 0.26
151128 1 8 16 12.72 101 0.36
151424 1 8 26 4.42 116 0.58
151302 1 8 31 1.29 72 0.26
151524 1 8 29 1 .92 140 0.32
151428 1 8 23 3.20 167 0.36
151987 1 8 24 2.53 95 0.34
151958 1 8 33 2.52 95 0.26
150774 1 8 23 13.93 14 0.20
151516 1 8 24 4.91 213 0.42
151466 1 8 28 3.31 85 0.50
151343 1 8 28 0.00 124 0.38
151309 1 8 31 1 .14 89 0.56
151219 1 8 33 6.81 90 0.23
151213 1 8 35 2.25 146 0.47
151408 1 8 24 2.96 176 0.87
151990 1 8 26 3.98 73 0.22
151332 1 8 23 0.00 61 0.24
151892 1 8 30 4.45 138 0.18
152041 1 8 41 3.18 66 0.00
151969 1 8 29 4.04 N/A 0.22
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
151997 1 8 31 2.79 62 0.26
150681 1 8 29 3.06 19 0.14
151993 1 8 27 4.37 61 0.38
151996 1 8 24 2.00 64 0.22
151520 1 8 21 2.28 193 0.40
151314 1 8 26 2.18 73 0.40
150827 1 8 38 1.15 63 0.30
151881 1 8 29 2.42 111 0.36
151690 1 8 23 4.59 119 0.63
150952 1 8 19 4.60 123 0.82
151885 1 8 28 3.45 117 0.16
151815 1 8 28 3.61 112 0.54
151086 1 8 34 5.52 N/A 0.42
150626 1 7 27 1.71 218 0.38
150424 1 7 28 2.00 92 0.44
150054 1 7 35 3.38 N/A 0.62
150342 1 7 30 4.69 137 0.50
150043 1 7 39 3.95 N/A N/A
150293 1 7 35 2.71 123 0.32
150621 1 7 26 1.79 69 0.22
150600 1 7 21 1 .39 37 N/A
150104 1 7 27 4.41 96 0.24
150625 1 7 25 0.98 48 0.38
150248 1 7 22 3.93 103 N/A
151855 1 7 31 0.31 81 0.46
151285 1 7 19 2.14 90 0.39
152011 1 7 32 0.14 4 0.28
151688 1 7 38 9.21 73 0.38
151985 1 7 37 9.88 133 0.26
151870 1 7 26 2.18 81 0.72
151619 1 7 32 1.00 59 0.52
150913 1 7 34 4.32 64 0.06
150878 1 7 36 3.21 65 0.34
151526 1 7 23 2.03 98 0.40
151125 1 7 31 1.68 233 0.26
152008 1 7 29 7.32 54 0.28
151617 1 7 32 2.00 95 0.50
151514 1 7 21 0.64 61 0.28
151464 1 7 29 1 .80 N/A N/A
151878 1 7 21 N/A 131 0.00
150724 1 7 27 1.94 167 0.38
150733 1 7 30 8.10 56 0.56
152046 1 7 34 4.15 N/A N/A
150657 1 7 39 3.41 112 0.28
151563 1 7 41 6.00 91 0.30
151268 1 7 39 7.00 179 0.35
151273 1 7 26 3.00 182 1.03
151274 1 7 26 1.00 8 0.32
152026 1 7 21 3.27 50 0.30
152344 1 7 22 1.10 52 0.28
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Sort Maternal AFP HCG UE3
Lab No Code Gestn Age (KU/L) (IU/ml) (nmol/L)
152707 1 7 27 1.00 50 0. 30
153405 1 7 29 N/A N/A N/A
152855 1 7 17 N/A 43 0.42
152368 1 7 29 N/A 60 0.48
153520 1 7 22 N/A N/A N/A
152920 1 7 29 N/A 50 0.46
152669 1 7 31 N/A N/A 0.48
153496 1 7 23 N/A N/A N/A
152925 1 7 21 N/A 83 0.14
152089 1 7 31 N/A 12 0.42
152926 1 7 29 N/A N/A N/A
152183 1 7 25 N/A 109 0.32
153146 1 7 27 N/A 106 0.54
153437 1 7 31 N/A N/A N/A
153020 1 7 23 N/A N/A N/A
152392 1 7 20 N/A 65 0.12
152871 1 7 30 N/A 63 0.30
152445 1 7 23 N/A 93 0.32
152194 1 7 19 N/A 56 0.26
153552 1 7 24 N/A N/A N/A
150423 1 6 36 2.00 16 0.48
151000 1 6 28 1 .39 N/A 0.24
151426 1 6 20 2.26 N/A 1. 76
150918 1 6 21 1.11 34 0. 52
151080 1 5 30 2.38 11 0.32
150905 1 6 29 1.42 73 0.22
150768 1 6 26 0.86 31 0.28
151817 1 5 19 2.00 N/A N/A
151622 1 6 33 N/A 71 0.28
151639 1 6 20 0.63 39 0.62
151640 1 6 24 0.94 108 0.62
152218 1 6 28 1.15 71 0.24
152283 1 6 35 2.00 104 0.76
153104 1 6 21 4.00 113 0.26
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Append ix II : Abnormal Pre gnancy Raw Data
Type Maternal Gestn. AFP HCG UE3
jab. No Abnorm. Age (Weeks) KU/L IU/ml nmol/L
151531 Tri-21 27 13 15.1 141 1.3
152056 Tri-21 24 8 2.1 85 0
157126 Tri-21 29 9 3.9 122 0.2
161233 Tri-21 25 13 8.0 96 1.58
162617 Tri-21 23 13 17.0 69 1.21
161566 Tri-21 29 9 1.0 136 0.50
162804 Tri-21 29 9 4.0 92 0
163154 Tri-21 36 7 1.0 78 0.28
162632 Tri-21 21 14 11.0 240 1.38
165443 Tri-21 31 11 1.0 45 0.18
165913 Tri-21 24 13 12.0 48 NA
163610 Tri-21 30 10 12.0 70 0.30
152190 Tri-21 35 14 13.2 38 0.75
923164 Tri-21 39 10 7.0 58 0.21
923428 Tri-21 28 13 10.0 47 1.29
968731 Tri-21 25 10 6.6 32 0
163898 Tri-18 33 13 12.0 13 0.60
911399 Tri-18 37 11 6.0 42 0
907057 Tri-18 35 11 6.0 10 0.24
911439 Tri-18 43 8 4.0 13 0.23
957231 Tri-18 39 12 10.7 31 0.23
151211 Tri-13 28 15 8.2 35 5.06
152390 Anenc. 8 3.0 227 0.94
154175 Anenc. 8 2.0 205 0. 74
160034 Anenc. 10 5.0 165 0.34
156492 Sp.Bif. 9 3.0 58 0.55
160086 Sp.Bif. 10 5.0 135 0.64
152514 Sp.Bif. 10 4.0 62 0. 74
161106 Sp.Bif. 11 6.0 40 0.54
165794 Sp.Bif. 11 11.0 63 0.67
152762 Sp.Bif. 12 19.0 77 1.31
160374 Sp.Bif. 12 14.0 16 1.07
160582 Sp.Bif. 12 19.0 82 0. 70
164348 Sp.Bif. 12 16.0 39 NA
153931 Sp.Bif. 13 18.0 39 0.91
152199 Sp.Bif. 14 64.0 44 2.04
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